Design Therapeutics
Design Therapeutics reported revenue of $0 million in fiscal 2025. Free cash flow was −$55 million. The diluted share count rose 1.3%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Design Therapeutics does
Design Therapeutics is a clinical-stage drug company, so it has no approved products. It is developing a new class of small-molecule drugs it calls GeneTAC molecules. They are meant to treat diseases caused by nucleotide repeat expansions, which are inherited errors in a gene where a short piece of DNA is repeated too many times.
Its lead program is for Friedreich ataxia, a disease that affects the brain and heart. Its drug candidate DT-216P2 is in a Phase 1/2 trial called RESTORE-FA. The FDA placed the program on clinical hold in June 2025 and lifted it in December 2025. The company expects an update on its effect on frataxin levels in the second half of 2026.
A second candidate, DT-168, is an eye drop for Fuchs endothelial corneal dystrophy, a disease of the cornea. It finished a Phase 1 trial in healthy volunteers in 2025. The company also has other research programs, and it relies on money it raises to fund its work.
Its biggest risks, as it describes them
- Losses since its start, with more expected, and it may never become profitable.
- It is early in development, and its drugs use new technology that makes results and timing hard to predict.
- Its drug candidates may cause side effects that delay or stop their development.
- Regulatory approval is lengthy and uncertain, and competitors may reach the market first.
Income statement
Design Therapeutics lost money in fiscal 2025: a net loss of $70 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 384 | 330 | 282 | 246 | 220 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 73.0x | 31.1x | 29.6x | 29.3x | 17.1x |
| Quick ratio | 73.0x | 31.1x | 29.6x | 29.3x | 17.1x |
Cash flow
Projections
Project Design Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Design Therapeutics says to expect
- DT-216P2: registrational plan update and data timing
Design expects to provide an update on its registrational plans in the fourth quarter of 2026, with data following 12 weeks of treatment expected in the first quarter of 2027.
Insider trades
No officer, director or 10% owner of Design Therapeutics reported buying or selling its shares on the open market between November 20, 2025 and November 19, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | 26.80 | 27.06 | 15.76 |
| Accruals ratio | −2.6% | −2.4% | −6.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | — |
Compare
Put Design Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Design Therapeutics | FY25 | — | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 0 | — | — | — | 0 | 0 |
| Revenue growth | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Research and development | 6 | 25 | 49 | 57 | 44 | 59 |
| Operating income | −8 | −36 | −68 | −78 | −62 | −80 |
| Net income | −8 | −36 | −63 | −67 | −50 | −70 |
| Diluted EPS (US$) | −0.52 | −0.77 | −1.14 | −1.19 | −0.88 | −1.22 |
| Diluted shares (millions) | 16 | 46 | 56 | 56 | 57 | 57 |
| Cash flow | ||||||
| Cash from operations | −9 | −29 | −51 | −59 | −43 | −54 |
| Capital expenditure | 0 | 2 | 1 | 0 | 0 | 0 |
| Free cash flow | −9 | −31 | −52 | −59 | −43 | −55 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 5 | 11 | 13 | 13 | 14 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 36 | 384 | 330 | 282 | 246 | 220 |
| Debt incl. finance leases | — | — | — | — | — | — |
| Total assets | 36 | 391 | 341 | 290 | 252 | 226 |
| Total liabilities | 2 | 8 | 14 | 12 | 10 | 14 |
| Shareholders' equity | −11 | 382 | 327 | 278 | 242 | 212 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −3,685.8% | — | — | — | — | — |
| Net margin | −3,663.7% | — | — | — | — | — |
| Free cash flow margin | −3,869.5% | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — |
| Return on equity | — | −19.2% | −17.9% | −22.1% | −19.1% | −30.7% |
| Return on assets | — | −16.6% | −17.3% | −21.2% | −18.3% | −29.2% |
| Net debt to EBITDA | — | — | — | — | — | — |